Cosmo Innovations Founder Eyes Global Rollout of SkinGate, IPO by 2027

After nearly three decades in aesthetic medicine and light therapy, Dr. Matthew Jafarzadeh is betting on a new wave of consumer healthcare innovation. The founder and CEO of Cosmo Innovations has unveiled SkinGate — a skincare infusion device he believes could reshape the $65 billion home beauty tech market.

Speaking at Emergence 2025, Dr. Jafarzadeh described SkinGate as “the next evolution in skincare delivery.” The patented device combines radio frequency, LED light, galvanic technology, and real-time skin analysis to deliver measured doses of active serums, aiming to significantly improve absorption and efficacy compared to manual application.

“Manual skincare application leads to inconsistent results — not to mention hygiene issues,” he said. “We’ve engineered a capsule-based delivery system that ensures uniform treatment with minimal waste, tailored to the user’s individual skin profile.”

The product sits within a broader portfolio developed by Cosmo Innovations — a holding company that owns more than 110 patents and trademarks across medtech, drug delivery, oral health, and consumer aesthetic technologies. The company is currently offering two investment pathways: through the parent entity, Cosmo Innovations, valued at A$45 million, or via its SkinGate subsidiary, Cosmo Skin, valued at A$30 million.

“Some investors are drawn to the entire IP suite, while others prefer to focus on SkinGate and its immediate commercial upside,” said Dr. Jafarzadeh. The company is currently seeking to raise USDA$3 million to fund manufacturing and international distribution of the SkinGate device.

Partnership discussions are also underway, with Cosmo targeting strategic alliances across marketing, distribution, and capital markets. “Our aim is not just to attract capital — we want smart capital,” he said, adding that Cosmo is targeting an IPO on either the Hong Kong Exchange or NASDAQ by 2027.

Longer term, Dr. Jafarzadeh has set his sights beyond skincare. With the launch of SkinGate expected to generate positive cash flow, he plans to commercialise additional IP already developed under the Cosmo umbrella. He also spoke of ambitions to establish Little Brain — an education initiative aimed at cultivating innovation and creative thinking in young children.

“Our technologies are designed to improve everyday health and wellbeing, but I also want to invest in the next generation of creators,” he said.

Reflecting on his experience at Emergence 2025, Dr. Jafarzadeh praised the event for its calibre of attendees and investor engagement. “It’s rare to find such a high-quality mix of stakeholders in one room. The atmosphere has been dynamic, supportive, and commercially minded.”

For Cosmo Innovations, the path forward is clear: capitalise on a maturing consumer health tech market, scale through strategic investment, and position Australian innovation on the global stage.